FDA-Cleared WellPD Tracks Parkinson's Symptoms at Home

People with Parkinson’s disease can now order a wrist-worn medical device that tracks their symptoms through the day and night at home. Empatica, a maker of clinical-grade wearables, launched WellPD on 28 October in a press release on PR Newswire. It describes the device and its companion app as “FDA-cleared and CE-marked”.

WellPD measures tremor, dyskinesia (involuntary movements that are often a side effect of medication) and bradykinesia (slowness of movement), along with sleep and physical activity. The app turns those readings into daily summaries, so users and their families can see how symptoms change around medication doses and talk about the patterns with their doctors.

What the FDA cleared

The US Food and Drug Administration’s 510(k) database lists clearance K260374 for the “Empatica Health Monitoring Platform for Parkinson’s Disease Monitoring”. The entry covers Empatica’s EmbracePlus and EmbraceMini wearables, its Empatica Care software, a “PKG Monitor by Empatica” and a care portal. The applicant is Empatica S.r.l. in Milan. The FDA received the submission on 5 February 2026 and found the system “substantially equivalent” to a device already on the market on 14 August. It is classed as a tremor transducer and was reviewed by the FDA’s neurology panel.

A 510(k) clearance is not the same as a full approval. It means the FDA accepted that the product is as safe and effective as an existing legally marketed device. Empatica’s release says WellPD is covered by this clearance.

How WellPD works

According to Empatica’s WellPD page, the wearable weighs 11 grams, has a stretchable fabric band, is waterproof and runs for 14 days on a charge. It sends data by Bluetooth to an app on a compatible smartphone, which also handles medication reminders. The page says the device needs a smartphone that stays with the wearer.

The app introduces a measure Empatica calls WellMove, which shows “how much of your day was spent with mild or no motor symptoms”. Readings are summarised daily, weekly and monthly.

The tracking comes from PKG Health, a Parkinson’s monitoring specialist that Empatica bought in 2025. The release says Empatica’s PKG algorithms “are supported by more than 70 peer-reviewed publications and used in more than 150 hospitals and clinical sites worldwide”. The release says the technology also supports Parkinson’s research by drug companies, universities and teaching hospitals, including clinical trials.

Matteo Lai, Empatica’s chief executive and co-founder, said the company was “bringing years of work in wearable technology and Parkinson’s research into a comfortable device that can be worn at home”. Dr Alessandro Di Rocco, who directs Parkinson’s and movement disorders care at Northwell Health in New York, said in the release that clinicians “need to understand their daily life at home—how they sleep, respond to treatment, and manage symptoms”.

Where it is available

The release says WellPD can be ordered in the United States, Canada, the UK, Australia, New Zealand and 14 countries in the European Economic Area: Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Malta, the Netherlands, Norway, Spain and Sweden. Empatica’s site says shipping starts on 23 November.

Buyers order directly from Empatica and choose a subscription. In the US, a prescription from a US-based healthcare practitioner is needed before the device ships, and buyers upload it after paying. Empatica has not published a price in its release.

A clinic-grade Parkinson’s measure moves into the home

This is TSN’s analysis. Parkinson’s is hard to judge in a short appointment. Symptoms can swing within hours as a dose takes effect and then wears off, and patients are often asked to remember or write down when they felt stiff, shaky or restless. Continuous wrist data can show those swings directly, which is why PKG-style monitoring has been used in clinics and trials for years. The step here is putting a cleared version in the hands of patients and carers, with summaries written for them rather than for a neurologist.

That is a real gain for people who manage the condition day to day. A week of data showing symptoms returning before the next dose is far easier to act on than a vague memory of a bad afternoon. It may also help families who care for someone with Parkinson’s understand what they are seeing.

The limits matter too. Empatica’s own page says WellPD “does not replace your healthcare provider’s clinical assessment”, and the FDA clearance rests on equivalence to an existing device, not on new evidence that patients do better with it. The price is not in the release, and a smartphone and subscription are part of the package, which could put it out of reach for some older users. It sits closer to the medical end of the wearables market than consumer gadgets such as Amazon’s Bee Frontier, and alongside other recent clearances TSN has covered, from an MRI-based breast cancer risk tool to an autism assessment aid. More health technology stories are collected in TSN’s Tech for Good round-up.